Eurosurveillance reviewers in 2023
(Source: Eurosurveillance)
Source: Eurosurveillance - January 4, 2024 Category: Infectious Diseases Authors: Eurosurveillance editorial team Source Type: research
Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023
We present early vaccine effectiveness (VE) estimates of the 2023 seasonal COVID-19 XBB.1.5 vaccine against COVID-19 hospitalisation and admission to an intensive care unit (ICU) in previously vaccinated adults ≥ 60 years in the Netherlands. We compared vaccination status of 2,050 hospitalisations including 92 ICU admissions with age group-, sex-, region- and date-specific population vaccination coverage between 9 October and 5 December 2023. VE against hospitalisation was 70.7% (95% CI: 66.6–74.3), VE against ICU admission was 73.3% (95% CI: 42.2–87.6). (Source: Eurosurveillance)
Source: Eurosurveillance - January 4, 2024 Category: Infectious Diseases Authors: C Henri van Werkhoven, Anne-Wil Valk, Bente Smagge, Hester E de Melker, Mirjam J Knol, Susan JM Hahn é, Susan van den Hof and Brechje de Gier Source Type: research
Increased number of cryptosporidiosis cases with travel history to Croatia might be related to swimming pools, Germany, 2023
In August and September 2023, an unusually high number of cryptosporidiosis cases identified by routine German surveillance had travelled to Croatia (n = 23). Nine cases had stayed in the same camping resort and seven further cases had stayed at other camping sites within 15 km. Based on our standardised questionnaires, the most likely source of infection was swimming pools (93%). Further environmental investigations on site might reveal potential common sources of contamination that could be targeted by control measures. (Source: Eurosurveillance)
Source: Eurosurveillance - January 4, 2024 Category: Infectious Diseases Authors: Anja Schoeps, Klara R öbl, Nicole Walter, Andrea Neute, Bernadette Walter, Inga Freudenau, Annette Jurke, Christiane Klier, Petra Heinmüller, Syamend Saeed, Jasmin Metz, Hendrik Wilking and Philipp Zanger Source Type: research
Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023
To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021–July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons≥ 80-years-old, while some protection remained in 65&#...
Source: Eurosurveillance - January 4, 2024 Category: Infectious Diseases Authors: Mario Font án-Vela, Esther Kissling, Nathalie Nicolay, Toon Braeye, Izaak Van Evercooren, Christian Holm Hansen, Hanne-Dorthe Emborg, Massimo Fabiani, Alberto Mateo-Urdiales, Ala'a AlKerwi, Susanne Schmitz, Jesús Castilla, Iván Martínez-Baz, Brechje d Source Type: research
Multinational collaboration in solving a European Salmonella Braenderup outbreak linked to imported melons, 2021
This article describes the outbreak and the benefits, successes, and challenges of multi-country collaboration for consideration in future large foodborne outbreaks across Europe. (Source: Eurosurveillance)
Source: Eurosurveillance - January 4, 2024 Category: Infectious Diseases Authors: Hannah L Moore, Martine Aabye, Ann Hoban, Bettina Rosner, Stine K Lefevre, Eva Litrup, Luise M üller, Steen Ethelberg, Sandra Simon, Sooria Balasegaram, Lesley Larkin, Cecilia Jernberg, Johanna Takkinen and EU/EEA/UK S. Braenderup Outbreak Investigation Source Type: research
Inventory study on completeness of tuberculosis case notifications in Poland in 2018
ConclusionsOur results suggest that the surveillance system captures≥ 90% of estimated TB cases in Poland; thus, the notification rate is a good proxy for the diagnosed TB incidence in Poland. Reporting delays causing discrepancies between data sources could be improved by the planned change from a paper-based to a digital reporting system. (Source: Eurosurveillance)
Source: Eurosurveillance - January 4, 2024 Category: Infectious Diseases Authors: Teresa Domaszewska, Maria Korzeniewska-Kosela, Barbara Hauer, Nita Perumal, Stefan Wesolowski, Walter Haas and Stefan Kroeger Source Type: research
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
ConclusionIt may be difficult to distinguish HZ, without a PCR result, from other zoster-like manifestations. In this study, VZV-PCR positive dermatomal eruptions occurring in the first weeks after immunisation with RZV were due to WT VZV, which is not unexpected as HZ is a common disease against which the vaccine is unlikely to provide full protection at this time. (Source: Eurosurveillance)
Source: Eurosurveillance - December 14, 2023 Category: Infectious Diseases Authors: Stefano Orru', Sibylle Bierbaum, Alexander Enk, Hartmut Hengel, Marcus Hoffelner, Daniela Huzly, Brigitte Keller-Stanislawski, Vera Mahler, Maja Mockenhaupt and Doris Oberle Source Type: research
Impact of the COVID-19 pandemic on prevalence of highly resistant microorganisms in hospitalised patients in the Netherlands, March 2020 to August 2022
ConclusionWe observed no substantial changes in HRMO prevalence in hospitalised patients during the COVID-19 pandemic. (Source: Eurosurveillance)
Source: Eurosurveillance - December 14, 2023 Category: Infectious Diseases Authors: Wieke Altorf-van der Kuil, Cornelia CH Wielders, Romy D Zwittink, Sabine C de Greeff, Dave A. Dongelmans, Ed J Kuijper, Daan W Notermans, Annelot F Schoffelen and on behalf of the study collaborators ISIS-AR study group Source Type: research
Prospective 25-year surveillance of prion diseases in France, 1992 to 2016: a slow waning of epidemics and an increase in observed sporadic forms
ConclusionWe observed a decrease of CJD infectious forms, demonstrating the effectiveness of measures to limit human exposure to exogenous prions. However, active surveillance is needed regarding uncertainties about future occurrences of vCJD, possible zoonotic potential of chronic wasting diseases in cervids and increasing trends of sCJD observed in France and other countries. (Source: Eurosurveillance)
Source: Eurosurveillance - December 14, 2023 Category: Infectious Diseases Authors: Ang éline Denouel, Jean-Philippe Brandel, Laurène Peckeu-Abboud, Danielle Seilhean, Elodie Bouaziz-Amar, Isabelle Quadrio, Jean-Baptiste Oudart, Sylvain Lehmann, Pantxika Bellecave, Jean-Louis Laplanche and Stéphane Haik Source Type: research
Mpox outbreak in France: epidemiological characteristics and sexual behaviour of cases aged 15 years or older, 2022
ConclusionChanges in cases’ characteristics during the epidemic, could reflect virus spread from people who were more to less behaviourally vulnerable to mpox between May and July, or MSM reducing numbers of sexual partners as recommended. (Source: Eurosurveillance)
Source: Eurosurveillance - December 14, 2023 Category: Infectious Diseases Authors: Catarina Krug, Arnaud Tarantola, Emilie Chazelle, Erica Foug ère, Annie Velter, Anne Guinard, Yvan Souares, Anna Mercier, Céline François, Katia Hamdad, Laetitia Tan-Lhernould, Anita Balestier, Hana Lahbib, Nicolas Etien, Pascale Bernillon, Virginie De Source Type: research
Job vacancies at the European Centre for Disease Prevention and Control (ECDC)
(Source: Eurosurveillance)
Source: Eurosurveillance - December 7, 2023 Category: Infectious Diseases Authors: Eurosurveillance editorial team Source Type: research
Respiratory syncytial virus infections – recent developments providing promising new tools for disease prevention
(Source: Eurosurveillance)
Source: Eurosurveillance - December 7, 2023 Category: Infectious Diseases Authors: Eeva K Broberg and Hanna Nohynek Source Type: research
A cluster of autochthonous dengue transmission in the Paris region – detection, epidemiology and control measures, France, October 2023
A cluster of three confirmed autochthonous dengue cases was detected in October 2023 in the Val-de-Marne department neighbouring Paris, France. This marks the northernmost transmission of dengue in Europe reported to date. The epidemiological and microbiological investigations and the vector control measures are described. This event confirms the need for early case detection and response to contain dengue in Europe, especially given the 2024 Summer Olympic and Paralympic Games, when millions of visitors will visit the Greater Paris area. (Source: Eurosurveillance)
Source: Eurosurveillance - December 7, 2023 Category: Infectious Diseases Authors: Nelly Fournet, Nathalie Voiry, Julian Rozenberg, Cl ément Bassi, Caroline Cassonnet, Anaïs Karch, Guillaume Durand, Gilda Grard, Gabriela Modenesi, Stevens-Boris Lakoussan, Nicolas Tayliam, Marta Zatta, Sébastien Gallien, on behalf of the investigation Source Type: research
Genomic characterisation of respiratory syncytial virus: a novel system for whole genome sequencing and full-length G and F gene sequences
To advance our understanding of respiratory syncytial virus (RSV) impact through genomic surveillance, we describe two PCR-based sequencing systems, (i) RSVAB-WGS for generic whole-genome sequencing and (ii) RSVAB-GF, which targets major viral antigens, G and F, and is used as a complement for challenging cases with low viral load. These methods monitor RSV genetic diversity to inform molecular epidemiology, vaccine effectiveness and treatment strategies, contributing also to the standardisation of surveillance in a new era of vaccines. (Source: Eurosurveillance)
Source: Eurosurveillance - December 7, 2023 Category: Infectious Diseases Authors: Mar ía Iglesias-Caballero, Sara Camarero-Serrano, Sarai Varona, Vicente Mas, Cristina Calvo, María Luz García, Juan García-Costa, Sonia Vázquez-Morón, Sara Monzón, Albert Campoy, Isabel Cuesta, Francisco Pozo and Inmaculada Casas Source Type: research
Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023
A monoclonal antibody for universal respiratory syncytial virus prophylaxis in infants has recently been licensed. We share our experiences of integrating nirsevimab into the regional immunisation programme in Galicia, Spain. After a 3-week hospital-based immunisation campaign with flexible individualised appointments and educational activities, nirsevimab uptake was 97.5% in the high-risk group, 81.4% in the catch-up group and 92.6% in infants born during the campaign. This successful implementation strategy can serve as a model and may inform other countries’ programmatic deliberations. (Source: Eurosurveillance)
Source: Eurosurveillance - December 7, 2023 Category: Infectious Diseases Authors: Federico Martin ón-Torres, Susana Mirás-Carballal and Carmen Durán-Parrondo Source Type: research
